ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-END / Endocrine and peptide-hormone analogs

Ganirelix

Also known as: Ganirelix acetate · Antagon · Orgalutran · Org 37462

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

Ganirelix is a synthetic decapeptide antagonist of GnRH. The acetate injection record is kept distinct from cetrorelix and other pathway analogs.

Evidence position

Regulated injection products and human evidence support Grade A for the defined finished presentations.

What the record does not establish

The label does not authenticate another sample or transfer sterility, concentration and device controls.

Sources

  • 01
    Ganirelix compound recordPubChem
    Shows
    Registry identity, structure, formula and synonyms for ganirelix
    Does not show
    Does not establish the acetate syringe formulation or lot quality
  • 02
    Ganirelix acetate injection prescribing informationDailyMed / U.S. National Library of Medicine
    Shows
    Current U.S. label, decapeptide identity and prefilled syringe presentation
    Does not show
    Does not qualify a different salt, concentration, syringe or source

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Ganirelix.Drugs / 2000 JanPMID 10718102 / DOI 10.2165/00003495-200059010-00007
  2. LHRH antagonists.Pharmaceutical biotechnology / 1998PMID 9760679 / DOI 10.1007/0-306-47384-4_7
  3. What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.Human reproduction update / 2023 May 2PMID 36594696 / DOI 10.1093/humupd/dmac040
  4. Synthesis and characterization of two potential impurities (des-ethyl-Ganirelix) generated in the Ganirelix manufacturing process.Journal of peptide science : an official publication of the European Peptide Society / 2023 SepPMID 36967632 / DOI 10.1002/psc.3489
  5. Ganirelix acetate.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists / 1999 Nov 15PMID 10582819 / DOI 10.1093/ajhp/56.22.2299

CLINICALTRIALS.GOV / FOUND RECORDS

  1. A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)COMPLETED / PHASE3 / Organon and CoNCT00696800 / DIRECT intervention MATCH: Ganirelix
  2. Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS PatientsUNKNOWN / PHASE4 / EugoniaNCT00417144 / DIRECT intervention MATCH: Ganirelix
  3. Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenACTIVE_NOT_RECRUITING / EARLY_PHASE1 / Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterNCT04037605 / DIRECT intervention MATCH: Ganirelix
  4. GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular GrowthUNKNOWN / PHASE4 / Assaf-Harofeh Medical CenterNCT05071339 / DIRECT intervention MATCH: Ganirelix
  5. Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) CyclesCOMPLETED / NA / Houston Fertility InstituteNCT01286051 / DIRECT intervention MATCH: Ganirelix

Related compounds

RM-END

Cetrorelix

Read entry →
RM-END

Degarelix

Read entry →
RM-END

Gonadorelin

Read entry →